NewAmsterdam Pharma (NAMSW) Competitors $9.47 +0.24 (+2.60%) As of 05/2/2025 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMSW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. NewAmsterdam Pharma vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics NewAmsterdam Pharma (NASDAQ:NAMSW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation. Which has higher earnings & valuation, NAMSW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56MN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the media favor NAMSW or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for NewAmsterdam Pharma. 180 Life Sciences' average media sentiment score of 0.59 beat NewAmsterdam Pharma's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment NewAmsterdam Pharma Neutral 180 Life Sciences Positive Is NAMSW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the MarketBeat Community favor NAMSW or ATNFW? NewAmsterdam Pharma and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformNewAmsterdam PharmaN/AN/A180 Life SciencesN/AN/A Summary180 Life Sciences beats NewAmsterdam Pharma on 2 of the 3 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMSW vs. The Competition Export to ExcelMetricNewAmsterdam PharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$125.50M$5.55B$8.03BDividend YieldN/A3.69%5.09%4.23%P/E RatioN/A3.2722.7518.87Price / SalesN/A4,272.58405.65106.84Price / CashN/A13.0238.1834.62Price / BookN/A34.206.794.34Net IncomeN/A-$90.45M$3.22B$248.06M7 Day Performance15.22%1.33%3.36%3.18%1 Month Performance29.73%5.25%6.92%8.28%1 Year Performance-13.59%92.44%16.16%5.04% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSWNewAmsterdam PharmaN/A$9.47+2.6%N/A-2.7%$0.00$45.56M0.0029Gap DownATNFW180 Life SciencesN/A$0.01-2.5%N/A-14.1%$0.00N/A0.007Positive NewsGap DownSXTPW60 Degrees PharmaceuticalsN/A$0.06+6.8%N/A-39.5%$0.00$607,574.000.002Gap UpDRTSWAlpha Tau MedicalN/A$0.22+6.8%N/A-14.9%$0.00N/A0.0080WENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-1.0%N/AN/A$0.00N/A0.0059Positive NewsGap DownBCTXWBriaCell TherapeuticsN/A$0.13+43.5%N/A-86.4%$0.00N/A0.008Gap UpHigh Trading VolumeCDIOWCardio DiagnosticsN/A$0.03-4.9%N/A-50.9%$0.00$34,890.000.007Positive NewsGap DownCTCXWCarmellN/A$0.03+6.8%N/A-63.7%$0.00$32,839.000.0014Gap UpCELUWCelularityN/A$0.04+9.4%N/AN/A$0.00$48.20M0.00220Positive NewsGap UpCEROWCERo TherapeuticsN/A$0.01-25.3%N/A-80.9%$0.00N/A0.008Positive NewsGap Up Related Companies and Tools Related Companies 180 Life Sciences Alternatives 60 Degrees Pharmaceuticals Alternatives Alpha Tau Medical Alternatives Anew Medical Alternatives Apollomics Alternatives BriaCell Therapeutics Alternatives Cardio Diagnostics Alternatives Carmell Alternatives Celularity Alternatives CERo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMSW) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMSW Stock Free NAMSW Stock Alerts